Navigation
The Company
Our Science
mTOR Pathway
nab
Technology Platform
Publications and Abstracts
Our Medicine
Our Medicine
Advanced Malignant PEComa
Pipeline
Patients
Overview
Patient Advocacy
Contact Us
General Contact
For Healthcare Professionals
Careers
Archive: October 15, 2022
Home
2022
October
15
15
Oct
2022
nab
-Sirolimus for patients with advanced malignant PEComa with or without prior mTOR inhibitors: Biomarker results from AMPECT and an expanded access program
0
0
October 15, 2022
October 15, 2022
